| Objective:To evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the lipid profile in patients with type 2 diabetes.Methods:We searched for randomized controlled trials(RCTs)in Pubmed,EMBASE,the Cochrane Library,Chinese National Knowledge Infrastructure(CNKI),Wanfang Database,VIP database from inception to 1 January 2019 and collect randomized controlled trials according to selection criter.The relevant data was extracted and meta-analysis was performed using RevMan5.3 software.Results:A total of 25 RCTs were included,involving a total of 5,213 patients.Meta-analysis showed that dapagliflozin reduced serum TG levels(mean difference =-0.09,95% CI:-0.15 to-0.03)and increased serum LDL-C(mean difference = 0.03),95% CI: 0.00 ~ 0.05),HDL-C level(mean difference = 0.07,95% CI: 0.04 ~ 0.09),compared with the control group,the difference was statistically significant.No significant difference was observed in serum TC levels between the two groups.Conclusion:Dapagliflozin reduced serum TG levels,and increased serum LDL-C,HDL-C levels.No significant difference was observed in serum TC levels between the two groups. |
PDF Full Text Request